Furlong CE - Search Results

1

Novel paraoxonase (PON1) nonsense and missense mutations predicted by functional genomic assay of PON1 status.

Jarvik GP, Jampsa R, Richter RJ, Carlson CS, Rieder MJ, Nickerson DA, Furlong CE. Jarvik GP, et al. Among authors: furlong ce. Pharmacogenetics. 2003 May;13(5):291-5. doi: 10.1097/00008571-200305000-00009. Pharmacogenetics. 2003. PMID: 12724622

2

Paraoxonase 1 (PON1) status and substrate hydrolysis.

Richter RJ, Jarvik GP, Furlong CE. Richter RJ, et al. Among authors: furlong ce. Toxicol Appl Pharmacol. 2009 Feb 15;235(1):1-9. doi: 10.1016/j.taap.2008.11.001. Epub 2008 Nov 13. Toxicol Appl Pharmacol. 2009. PMID: 19071155 Free PMC article.

3

Determination of paraoxonase 1 status without the use of toxic organophosphate substrates.

Richter RJ, Jarvik GP, Furlong CE. Richter RJ, et al. Among authors: furlong ce. Circ Cardiovasc Genet. 2008 Dec;1(2):147-52. doi: 10.1161/CIRCGENETICS.108.811638. Circ Cardiovasc Genet. 2008. PMID: 20031556 Free PMC article. No abstract available.

4

Paraoxonase 1 status as a risk factor for disease or exposure.

Richter RJ, Jarvik GP, Furlong CE. Richter RJ, et al. Among authors: furlong ce. Adv Exp Med Biol. 2010;660:29-35. doi: 10.1007/978-1-60761-350-3_4. Adv Exp Med Biol. 2010. PMID: 20221868 Free PMC article. Review.

5

Determination of paraoxonase 1 status and genotypes at specific polymorphic sites.

Richter RJ, Jampsa RL, Jarvik GP, Costa LG, Furlong CE. Richter RJ, et al. Among authors: furlong ce. Curr Protoc Toxicol. 2004 May;Chapter 4:Unit4.12. doi: 10.1002/0471140856.tx0412s19. Curr Protoc Toxicol. 2004. PMID: 20945303

6

Pharmacogenomic considerations of the paraoxonase polymorphisms.

Furlong CE, Cole TB, Jarvik GP, Costa LG. Furlong CE, et al. Pharmacogenomics. 2002 May;3(3):341-8. doi: 10.1517/14622416.3.3.341. Pharmacogenomics. 2002. PMID: 12052142 Review.

7

Functional genomic of the paraoxonase (PON1) polymorphisms: effects on pesticide sensitivity, cardiovascular disease, and drug metabolism.

Costa LG, Cole TB, Jarvik GP, Furlong CE. Costa LG, et al. Among authors: furlong ce. Annu Rev Med. 2003;54:371-92. doi: 10.1146/annurev.med.54.101601.152421. Epub 2001 Dec 3. Annu Rev Med. 2003. PMID: 12525679 Review.

8

Expression of human paraoxonase (PON1) during development.

Cole TB, Jampsa RL, Walter BJ, Arndt TL, Richter RJ, Shih DM, Tward A, Lusis AJ, Jack RM, Costa LG, Furlong CE. Cole TB, et al. Among authors: furlong ce. Pharmacogenetics. 2003 Jun;13(6):357-64. doi: 10.1097/00008571-200306000-00007. Pharmacogenetics. 2003. PMID: 12777966

9

Paraoxonase activity, but not haplotype utilizing the linkage disequilibrium structure, predicts vascular disease.

Jarvik GP, Hatsukami TS, Carlson C, Richter RJ, Jampsa R, Brophy VH, Margolin S, Rieder M, Nickerson D, Schellenberg GD, Heagerty PJ, Furlong CE. Jarvik GP, et al. Among authors: furlong ce. Arterioscler Thromb Vasc Biol. 2003 Aug 1;23(8):1465-71. doi: 10.1161/01.ATV.0000081635.96290.D3. Epub 2003 Jun 12. Arterioscler Thromb Vasc Biol. 2003. PMID: 12805074

10

Toxicity of chlorpyrifos and chlorpyrifos oxon in a transgenic mouse model of the human paraoxonase (PON1) Q192R polymorphism.

Cole TB, Walter BJ, Shih DM, Tward AD, Lusis AJ, Timchalk C, Richter RJ, Costa LG, Furlong CE. Cole TB, et al. Among authors: furlong ce. Pharmacogenet Genomics. 2005 Aug;15(8):589-98. doi: 10.1097/01.fpc.0000167327.08034.d2. Pharmacogenet Genomics. 2005. PMID: 16007003

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

173 results

Search Page